^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Non-nucleoside reverse transcriptase inhibitor

    Related drugs:
    5d
    The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants. (PubMed, Clin Transl Sci)
    These results suggest that concomitant use of quizartinib and moderate CYP3A inducers should be avoided. Concomitant use of weak CYP3A inducers does not warrant dose adjustment, since the impact on quizartinib exposure is clinically nonrelevant.
    P1 data • PK/PD data • Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Vanflyta (quizartinib) • efavirenz
    6d
    The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs (clinicaltrials.gov)
    P=N/A, N=0, Approved for marketing, Tibotec Pharmaceuticals, Ireland | N=5178 --> 0
    Enrollment change
    12d
    Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK (clinicaltrials.gov)
    P1, N=60, Recruiting, Indiana University | Trial completion date: Apr 2027 --> Dec 2026 | Trial primary completion date: Apr 2027 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    efavirenz
    15d
    Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK (clinicaltrials.gov)
    P1, N=60, Recruiting, Indiana University | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    efavirenz
    19d
    Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome. (clinicaltrials.gov)
    P1, N=64, Recruiting, Orvida Pharma (formerly Kamari Pharma) | Trial completion date: Feb 2026 --> Nov 2026 | Trial primary completion date: Feb 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    TRPV3 (Transient Receptor Potential Cation Channel Subfamily V Member 3)
    29d
    TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (clinicaltrials.gov)
    P3, N=180, Completed, Janssen Sciences Ireland UC | Active, not recruiting --> Completed
    Trial completion
    1m
    Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (clinicaltrials.gov)
    P1/2, N=90, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Aug 2027 --> Mar 2029
    Trial completion date
    2ms
    PANNA-B PK: Study on PhArmacokinetics of First liNe Antiretrovirals in Healthy Breastfeeding Volunteers (clinicaltrials.gov)
    P4, N=20, Completed, Radboud University Medical Center | Recruiting --> Completed | N=36 --> 20 | Trial completion date: Dec 2024 --> Apr 2025
    Trial completion • Enrollment change • Trial completion date
    2ms
    IM-CAPABLE: IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas (clinicaltrials.gov)
    P=N/A, N=55, Active, not recruiting, University of Nebraska | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel (clinicaltrials.gov)
    P1, N=40, Completed, International Partnership for Microbicides, Inc. | Phase classification: P1/2 --> P1
    Phase classification
    3ms
    DORDOL: Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch (clinicaltrials.gov)
    P3, N=150, Recruiting, Chelsea and Westminster NHS Foundation Trust | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NEFL (Neurofilament Light Chain)
    3ms
    Efavirenz for the Treatment of Creutzfeldt-Jakob Disease (clinicaltrials.gov)
    P3, N=246, Not yet recruiting, Xuanwu Hospital, Beijing
    New P3 trial
    |
    efavirenz